Skip to main content
Atencion Primaria logoLink to Atencion Primaria
letter
. 2013 Apr 5;25(4):281. [Article in Spanish] doi: 10.1016/S0212-6567(00)78501-5

Espironolactona en insuficiencia cardíaca

F López Herrero 1, J Pardo Álvarez 1
PMCID: PMC7679507  PMID: 10795445

The content is available as a PDF (35.3 KB).

Bibliografía

  • 1.López-Rodríguez I., Castro-Beiras A., Asensi A., Bacariza F., Rábade J.M., Muñiz J. Normas básicas de manejo de la insuficiencia cardíaca en atención primaria. Aten Primaria. 1999;24:289–294. [PubMed] [Google Scholar]
  • 2.Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Pérez A. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717. doi: 10.1056/NEJM199909023411001. [DOI] [PubMed] [Google Scholar]
  • 3.Weber K.T. Aldosterone and spironolactone in heart failure. N Engl J Med. 1999;341:753–755. doi: 10.1056/NEJM199909023411009. [DOI] [PubMed] [Google Scholar]
  • 4.Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Preassure (JNC VI) Arch Intern Med. 1997;157:2413–2446. doi: 10.1001/archinte.157.21.2413. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES